FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2027279736> ?p ?o ?g. }

• W2027279736 endingPage "2778" @default.
• W2027279736 startingPage "2770" @default.
• W2027279736 abstract "Abstract BACKGROUND: The standard treatment of osteosarcoma includes cisplatin and high‐dose methotrexate (HDMTX); both agents exert significant toxicity, and HDMTX requires complex pharmacokinetic monitoring and leucovorin rescue. In the previous OS91 trial, the treatment of localized disease with carboplatin, ifosfamide, doxorubicin, and HDMTX yielded outcomes comparable to those of cisplatin‐based regimens and caused less toxicity. To build on this experience, the authors conducted a multi‐institutional trial (OS99) that evaluated the efficacy of carboplatin, ifosfamide, and doxorubicin without HDMTX in patients with newly diagnosed, localized, resectable osteosarcoma. METHODS: Treatment was comprised of 12 cycles of chemotherapy administered over 35 weeks: 3 cycles of carboplatin (dose targeted to area under the concentration‐time curve of 8 mg/mL × min on Day 1) and ifosfamide (at a dose of 2.65 g/m 2 daily ×3 days) and 1 cycle of doxorubicin (at a dose of 25 mg/m 2 daily ×3 days) before surgical resection, followed by 2 additional cycles of the combination of carboplatin and ifosfamide and 3 cycles each of doxorubicin (25 mg/m 2 daily ×2 days) combined with ifosfamide or carboplatin. RESULTS: A total of 72 eligible patients (median age, 13.4 years) were enrolled between May 1999 and May 2006. Forty of the 66 (60.6%) evaluable patients had good histologic responses (>90% tumor necrosis) to preoperative chemotherapy. The estimated 5‐year event‐free survival rate was 66.7% ± 7.0% for the OS99 trial compared with 66.0% ± 6.8% for the OS91 trial ( P = .98). The estimated 5‐year survival rate was 78.9% ± 6.3% for the OS99 trial and 74.5% ± 6.3% for the OS91 trial ( P = .40). CONCLUSIONS: The regimen used in the OS99 trial was found to produce outcomes comparable to those of cisplatin‐containing or HDMTX‐containing regimens. This therapy offers a good alternative for patients, particularly those who demonstrate an intolerance of HDMTX, and for institutions that cannot provide pharmacokinetic monitoring for MTX. Cancer 2011. © 2011 American Cancer Society." @default.
• W2027279736 created "2016-06-24" @default.
• W2027279736 creator A5002520656 @default.
• W2027279736 creator A5006851213 @default.
• W2027279736 creator A5009480626 @default.
• W2027279736 creator A5012423746 @default.
• W2027279736 creator A5032946348 @default.
• W2027279736 creator A5048193615 @default.
• W2027279736 creator A5054596213 @default.
• W2027279736 creator A5059549851 @default.
• W2027279736 creator A5060308592 @default.
• W2027279736 creator A5090167515 @default.
• W2027279736 date "2011-01-10" @default.
• W2027279736 modified "2023-10-18" @default.
• W2027279736 title "Frontline treatment of localized osteosarcoma without methotrexate" @default.
• W2027279736 cites W1515197095 @default.
• W2027279736 cites W1762813577 @default.
• W2027279736 cites W1854116296 @default.
• W2027279736 cites W1911184691 @default.
• W2027279736 cites W1924934937 @default.
• W2027279736 cites W1944507750 @default.
• W2027279736 cites W1954845453 @default.
• W2027279736 cites W1980809682 @default.
• W2027279736 cites W1994351520 @default.
• W2027279736 cites W2000456697 @default.
• W2027279736 cites W2017679589 @default.
• W2027279736 cites W2021276267 @default.
• W2027279736 cites W2054160144 @default.
• W2027279736 cites W2063759313 @default.
• W2027279736 cites W2071154034 @default.
• W2027279736 cites W2073140442 @default.
• W2027279736 cites W2081341733 @default.
• W2027279736 cites W2103405666 @default.
• W2027279736 cites W2104953667 @default.
• W2027279736 cites W2123745849 @default.
• W2027279736 cites W2142136189 @default.
• W2027279736 cites W2152308356 @default.
• W2027279736 cites W2156859939 @default.
• W2027279736 cites W2164614740 @default.
• W2027279736 cites W2165678358 @default.
• W2027279736 cites W2288042566 @default.
• W2027279736 cites W2338213887 @default.
• W2027279736 cites W27278923 @default.
• W2027279736 cites W4246742253 @default.
• W2027279736 doi "https://doi.org/10.1002/cncr.25715" @default.
• W2027279736 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3535449" @default.
• W2027279736 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21656756" @default.
• W2027279736 hasPublicationYear "2011" @default.
• W2027279736 type Work @default.
• W2027279736 sameAs 2027279736 @default.
• W2027279736 citedByCount "84" @default.
• W2027279736 countsByYear W20272797362012 @default.
• W2027279736 countsByYear W20272797362013 @default.
• W2027279736 countsByYear W20272797362014 @default.
• W2027279736 countsByYear W20272797362015 @default.
• W2027279736 countsByYear W20272797362016 @default.
• W2027279736 countsByYear W20272797362017 @default.
• W2027279736 countsByYear W20272797362018 @default.
• W2027279736 countsByYear W20272797362019 @default.
• W2027279736 countsByYear W20272797362020 @default.
• W2027279736 countsByYear W20272797362021 @default.
• W2027279736 countsByYear W20272797362022 @default.
• W2027279736 countsByYear W20272797362023 @default.
• W2027279736 crossrefType "journal-article" @default.
• W2027279736 hasAuthorship W2027279736A5002520656 @default.
• W2027279736 hasAuthorship W2027279736A5006851213 @default.
• W2027279736 hasAuthorship W2027279736A5009480626 @default.
• W2027279736 hasAuthorship W2027279736A5012423746 @default.
• W2027279736 hasAuthorship W2027279736A5032946348 @default.
• W2027279736 hasAuthorship W2027279736A5048193615 @default.
• W2027279736 hasAuthorship W2027279736A5054596213 @default.
• W2027279736 hasAuthorship W2027279736A5059549851 @default.
• W2027279736 hasAuthorship W2027279736A5060308592 @default.
• W2027279736 hasAuthorship W2027279736A5090167515 @default.
• W2027279736 hasBestOaLocation W20272797362 @default.
• W2027279736 hasConcept C126322002 @default.
• W2027279736 hasConcept C126894567 @default.
• W2027279736 hasConcept C141071460 @default.
• W2027279736 hasConcept C142724271 @default.
• W2027279736 hasConcept C143998085 @default.
• W2027279736 hasConcept C2776694085 @default.
• W2027279736 hasConcept C2777506904 @default.
• W2027279736 hasConcept C2777760704 @default.
• W2027279736 hasConcept C2778239845 @default.
• W2027279736 hasConcept C2781059491 @default.
• W2027279736 hasConcept C2781303535 @default.
• W2027279736 hasConcept C2781451048 @default.
• W2027279736 hasConcept C71924100 @default.
• W2027279736 hasConceptScore W2027279736C126322002 @default.
• W2027279736 hasConceptScore W2027279736C126894567 @default.
• W2027279736 hasConceptScore W2027279736C141071460 @default.
• W2027279736 hasConceptScore W2027279736C142724271 @default.
• W2027279736 hasConceptScore W2027279736C143998085 @default.
• W2027279736 hasConceptScore W2027279736C2776694085 @default.
• W2027279736 hasConceptScore W2027279736C2777506904 @default.
• W2027279736 hasConceptScore W2027279736C2777760704 @default.
• W2027279736 hasConceptScore W2027279736C2778239845 @default.
• W2027279736 hasConceptScore W2027279736C2781059491 @default.

• next